Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

PATENTS

Contractual solutions to overcome drug scarcity during pandemics and epidemics

Nature Biotechnology volume 40, pages 301–302 (2022)Cite this article

Subjects

Licensing provisions that obligate recipients of government funding to share relevant technology and know-how for scarce drugs during pandemics and epidemics can reduce shortages and overcome obstacles that intellectual property rights present.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Torres, I. et al. Lancet 397, 1804 (2021).

    Article  CAS  Google Scholar 

  2. Kumar, S. Patently-O (January 2021); https://patentlyo.com/patent/2021/01/shortages-compulsory-licensing.html

  3. Maxmen, A. Nature 597, 455–457 (2021).

    Article  CAS  Google Scholar 

  4. World Health Organization. WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines (May 2021); https://www.who.int/news/item/05-05-2021-who-director-general-commends-united-states-decision-to-support-temporary-waiver-on-intellectual-property-rights-for-covid-19-vaccines

  5. Office of the US Trade Representative. Statement from Ambassador Katherine Tai on the Covid-19 Trips Waiver (May 2021); https://ustr.gov/about-us/policy-offices/press-office/press-releases/2021/may/statement-ambassador-katherine-tai-covid-19-trips-waiver

  6. European Union. EU proposes a strong multilateral trade response to the COVID-19 pandemic (June 2021); https://ec.europa.eu/commission/presscorner/detail/en/IP_21_2801

  7. Price, W. N. II, Rai, A. K. & Minssen, T. Science 369, 912–914 (2020).

    Article  CAS  Google Scholar 

  8. Baker, S. & Koons, C. Inside Operation Warp Speed’s $18 billion sprint for a vaccine. Bloomberg Businessweek (October 2020); https://www.bloomberg.com/news/features/2020-10-29/inside-operation-warp-speed-s-18-billion-sprint-for-a-vaccine

  9. Rowland, C. & McGinley, L. Merck will help make Johnson & Johnson coronavirus vaccine as rivals team up to help Biden accelerate shots. Washington Post (March 2021); https://www.washingtonpost.com/health/2021/03/02/merck-johnson-and-johnson-covid-vaccine-partnership/

  10. Kumar, S. Conn. Law Rev. 54, 57–104 (2022).

    Google Scholar 

  11. Rutschman, A. S. UCLA Law Rev. 65, 1200–1266 (2018).

    Google Scholar 

  12. Kelly, H. Bull. World Health Organ. 89, 540–541 (2011).

    Article  Google Scholar 

  13. Rutschman, A. S. & Barnes-Weise, J. The COVID-19 vaccine patent waiver: the wrong tool for the right goal. Harvard Bill of Health (May 2021); https://blog.petrieflom.law.harvard.edu/2021/05/05/covid-vaccine-patent-waiver/

Download references

Author information

Authors and Affiliations

  1. University of Houston Law Center, Houston, Texas, USA

    Sapna Kumar

  2. Institute for Intellectual Property and Information Law, Houston, Texas, USA

    Sapna Kumar

  3. Saint Louis University School of Law, Saint Louis, Missouri, USA

    Ana Santos Rutschman

  4. Saint Louis University Peiper & Wang Institute for Vaccine Science and Policy, Saint Louis, Missouri, USA

    Ana Santos Rutschman

Authors
  1. Sapna Kumar
    View author publications

    Search author on:PubMed Google Scholar

  2. Ana Santos Rutschman
    View author publications

    Search author on:PubMed Google Scholar

Contributions

Both authors contributed equally to the work presented in the paper.

Corresponding author

Correspondence to Sapna Kumar.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kumar, S., Rutschman, A.S. Contractual solutions to overcome drug scarcity during pandemics and epidemics. Nat Biotechnol 40, 301–302 (2022). https://doi.org/10.1038/s41587-022-01241-1

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-022-01241-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing